Femyso: Affected lot may contain two green Mifepristone cartons or two pink Misoprostol cartons instead of one of each.
Brand(s)
Last updated
Summary
Product
Femyso Mifepristone 200mg / Misoprostol 200 mcg tablet
Issue
Health products - Packaging
What to do
Consult your healthcare provider prior to discontinuing use of the affected product, or if you have any health concerns.
Affected products
| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot Number |
|---|---|---|---|---|---|
| Lupin Pharma Canada Ltd. | Femyso Mifepristone 200 mg / Misoprostol 200 mcg tablet | DIN 02560569 | Kit, Tablet | Mifepristone 200 mg / Misoprostol 200 mcg | NR02557A |
Issue
Affected lot may contain two green Mifepristone cartons or two pink Misoprostol cartons instead of one of each.
What you should do
- Verify whether your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product, or if you have any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Lupin Pharma Canada Limited.
550-1111 rue St-Charles Ouest
Longueuil, QC, J4K 5G4
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type II
Identification number
RA-82416
Get notified
Receive emails about new and updated recall and safety alerts.